💊FDA & PHARMA TODAY
Bardoxolone Methyl (RTA 402) Designated for the Treatment of Diabetic Kidney Disease under the Priority Review and Designation System by the Ministry of Health, Labour and Welfare
Kyowa Hakko Kirin News Releases /
http://www.kyowa-kirin.com/news_releases/2018/pdf/e20180328_01.pdf
Mar.28.2018……U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for Previously Treated Patients with MSI-H or dMMR Metastatic Colorectal Cancer for Priority Review